Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Burgess

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infectionsDavid S Burgess
Journal of Managed Care Pharmacy : JMCP|June 10, 2009
Curbing resistance development: maximizing the utility of available agentsDavid S Burgess
Pathogens and Disease|August 1, 2019
Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical centerBrandon Kulengowski, David S Burgess
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosaDavid S Burgess, Surakit Nathisuwan
Clinical Therapeutics|August 17, 2002
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosingDavid S Burgess, Travis Waldrep
Antimicrobial Agents and Chemotherapy|May 2, 2018
Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with VancomycinW Cliff Rutter, David S Burgess
Clinical Therapeutics|January 27, 2009
Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002Christopher R Frei, David S Burgess
Journal of Clinical Medicine Research|March 23, 2013
Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniaeGrace C Lee, David S Burgess
Pharmacotherapy|September 17, 2005
Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulationChristopher R Frei, David S Burgess
International Journal of Antimicrobial Agents|July 1, 2004
In vitro activity of parenteral Beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum Beta-lactamase producing Klebsiella pneumoniaeDavid S Burgess, Ronald G Hall
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infectionsDavid S Burgess
Journal of Managed Care Pharmacy : JMCP|June 10, 2009
Curbing resistance development: maximizing the utility of available agentsDavid S Burgess
Pathogens and Disease|August 1, 2019
Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical centerBrandon Kulengowski, David S Burgess
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosaDavid S Burgess, Surakit Nathisuwan
Clinical Therapeutics|August 17, 2002
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosingDavid S Burgess, Travis Waldrep
Antimicrobial Agents and Chemotherapy|May 2, 2018
Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with VancomycinW Cliff Rutter, David S Burgess
Clinical Therapeutics|January 27, 2009
Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002Christopher R Frei, David S Burgess
Journal of Clinical Medicine Research|March 23, 2013
Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniaeGrace C Lee, David S Burgess
Pharmacotherapy|September 17, 2005
Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulationChristopher R Frei, David S Burgess
International Journal of Antimicrobial Agents|July 1, 2004
In vitro activity of parenteral Beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum Beta-lactamase producing Klebsiella pneumoniaeDavid S Burgess, Ronald G Hall
Pageof 8